Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt

British Journal of Pharmacology

Volumn 164, Issue 3, 2011, Pages 946-957

  Aceros, H ^a   Farah, G ^a   Cobos Puc, L ^a   Stabile, A M ^a   Noiseux, N ^a   Mukaddam Daher, S ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Akt; apoptosis; cardiomyocytes; cytokines; echocardiography; flow cytometry; left ventricular hypertrophy; p38 MAPK

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; MOXONIDINE; NORADRENALIN; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PERFORMANCE; HEART RATE; HISTOLOGY; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT RESPONSE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CELL DEATH; CELL SURVIVAL; COLLAGEN; CYTOKINES; ECHOCARDIOGRAPHY; FIBROBLASTS; FIBROSIS; HEART; HEART RATE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; INFLAMMATION; MYOCARDIUM; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 80052554634     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01355.x     Document Type: Article

References (43)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, et al,. (2007). Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 49: 362-368. (Pubitemid 47000310)
3. Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, et al,. (2009). PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res 83: 501-510.
4. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, et al,. (2001). Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104: 1292-1298. (Pubitemid 32848120)
5. deBlois D, Tea B-S, Beaudry D, Hamet P, (2005). Regulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage. Can J Physiol Pharmacol 83: 29-41. (Pubitemid 40754773)
6. Bozkurt B, Kribbs SB, Clubb FJ, Jr, Michael LH, Didenko VV, Hornsby PJ, et al,. (1998). Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97: 1382-1391. (Pubitemid 28182677)
7. Colombo F, Gosselin H, El-Helou V, Calderone A, (2003). Beta-adrenergic receptor-mediated DNA synthesis in neonatal rat cardiac fibroblasts proceeds via a phosphatidylinositol 3-kinase dependent pathway refractory to the antiproliferative action of cyclic AMP. J Cell Physiol 195: 322-330. (Pubitemid 36384305)
8. Communal C, Singh K, Pimentel DR, Colucci WS, (1998). Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98: 1329-1334. (Pubitemid 28443398)
9. Dhingra S, Sharma AK, Singla DK, Singal PK, (2007). p38 and ERK1/2 MAPKs mediate the interplay of TNF-alpha and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 293: 3524-3531.
10. El-Ayoubi R, Gutkowska J, Regunathan S, Mukaddam-Daher S, (2002). Imidazoline receptors in the heart: characterization, distribution, and regulation. J Cardiovasc Pharmacol 39: 875-883. (Pubitemid 34538818)
11. Esposito G, Perrino C, Schiattarella GG, Belardo L, di Pietro E, Franzone A, et al,. (2010). Induction of mitogen-activated protein kinases is proportional to the amount of pressure overload. Hypertension 55: 137-143.
12. Foo RS, Mani K, Kitsis RN, (2005). Death begets failure in the heart. J Clin Invest 115: 565-571. (Pubitemid 40322226)
13. Fotheringham JA, Mayne MB, Grant JA, Geiger JD, (2004). Activation of adenosine receptors inhibits tumor necrosis factor-alpha release by decreasing TNF-alpha mRNA stability and p38 activity. Eur J Pharmacol 497: 87-95. (Pubitemid 39099216)
14. Fu YC, Chi CS, Yin SC, Hwang B, Chiu YT, Hsu SL, (2004). Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signalling pathway. Cardiovasc Res 62: 558-567. (Pubitemid 38648970)
15. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K, (2000). Akt promotes survival of cardiomyocytes in vitro and protects against ischemia reperfusion injury in mouse heart. Circulation 101: 660-667. (Pubitemid 30094738)
16. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Arenare F, Spaziani D, et al,. (2009). Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension 53: 205-209.
17. Haczynski J, Spring A, Przewlocka-Kosmala M, Flasinski J, (2001). Effect of moxonidine on left ventricular hypertrophy in hypertensive patients. J Clin Basic Cardiol 4: 61-65. (Pubitemid 32422529)
18. Heineke J, Molkentin JD, (2006). Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600. (Pubitemid 44325350)
19. Kai H, Kuwahara F, Tokuda K, Imaizumi T, (2005). Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28: 483-490. (Pubitemid 41195386)
20. Kumar S, Seth S, Jaiswal A, Enjamoori R, Dinda AK, Ray R, et al,. (2009). Chronic beta-adrenergic activation-induced left ventricular systolic dysfunction is associated with systemic release of TNF-alpha and IL-1-beta in rats. Pharmacol Rep 61: 870-876.
21. Leicht M, Briest W, Zimmer HG, (2003). Regulation of norepinephrine- induced proliferation in cardiac fibroblasts by interleukin-6 and p42/p44 mitogen activated protein kinase. Mol Cell Biochem 243: 65-72. (Pubitemid 36240552)
22. Li M, Georgakopoulos D, Lu G, Hester L, Kass DA, Hasday J, et al,. (2005). p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 111: 2494-2502. (Pubitemid 40696138)
23. Liang Q, Elson AC, Gerdes AM, (2006). p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats. J Card Fail 12: 479-486. (Pubitemid 46106984)
24. Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y, et al,. (2004). Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110: 692-699. (Pubitemid 39056268)
25. Liu HR, Gao F, Tao L, Yan WL, Gao E, Christopher TA, et al,. (2004). Antiapoptotic mechanisms of benidipine in the ischemic/reperfused heart. Br J Pharmacol 142: 627-634. (Pubitemid 38969657)
26. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL, (2010). Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56: 225-231.
27. Mitrovic V, Hamel M, Miric M, Thormann J, Hamm C, (2001). Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation. Z Kardiol 90: 953-963. (Pubitemid 34072951)
28. Mukaddam-Daher S, Menaouar A, Paquette P-A, Jankowski M, Gutkowska J, Gillis M-A, et al,. (2009). Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in Stroke Prone Spontaneous Hypertensive Rats. Hypertension 53: 775-781.
29. Neri M, Cerretani D, Fiaschi AI, Laghi PF, Lazzerini PE, Maffione AB, et al,. (2007). Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats. J Cell Mol Med 11: 156-170. (Pubitemid 46439634)
30. Nonaka-Sarukawa M, Okada T, Ito T, Yamamoto K, Yoshioka T, Nomoto T, et al,. (2008). Adeno-associated virus vector-mediated systemic interleukin-10 expression ameliorates hypertensive organ damage in Dahl salt-sensitive rats. J Gene Med 10: 368-374. (Pubitemid 351517092)
31. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH, (2004). The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37: 449-471. (Pubitemid 38953373)
32. Paquette P-A, Duguay D, El-Ayoubi R, Menaouar A, Danalache B, Gutkowska J, et al,. (2008). Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation. Br J Pharmacol 153: 459-467. (Pubitemid 351199016)
33. Petrov VV, Fagard RH, Lijnen PJ, (2002). Stimulation of collagen production by transforming growth factor-β1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39: 258-263. (Pubitemid 34165225)
34. Pierdomenico SD, Lapenna D, Cuccurullo F, (2008). Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 21: 464-470. (Pubitemid 351450868)
35. Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati C, et al,. (2002). Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 39: 2005-2011. (Pubitemid 34628283)
36. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous S, Esler MD, (2003). Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108: 560-565. (Pubitemid 36961170)
37. Soesanto W, Lin HY, Hu E, Lefler S, Litwin SE, Sena S, et al,. (2009). Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 54: 1321-1327.
38. Streicher JM, Ren S, Herschman H, Wang Y, (2010). MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res 106: 1434-1443.
39. Taniyama Y, Ito M, Sato K, Kuester C, Veit K, Tremp G, et al,. (2005). Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. J Mol Cell Cardiol 38: 375-385. (Pubitemid 40215207)
40. Van Kerckhoven R, van Veen TA, Boomsma F, Saxena PR, Schoemaker RG, (2000). Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol 397: 113-120. (Pubitemid 30323817)
41. Verma A, Solomon SD, (2009). Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am 93: 647-664.
42. Wang Y, Huang S, Sah VP, Ross J, Jr, Brown JH, Han J, et al,. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273: 2161-2168. (Pubitemid 28069266)
43. Wenzel RR, Spieker L, Qui S, Shaw S, Luscher TF, Noll G, (1998). I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension 32: 1022-1027. (Pubitemid 29001430)